key: cord-0963514-kbxymn7y
authors: Bricker, Traci L.; Darling, Tamarand L.; Hassan, Ahmed O.; Harastani, Houda H.; Soung, Allison; Jiang, Xiaoping; Dai, Ya-Nan; Zhao, Haiyan; Adams, Lucas J.; Holtzman, Michael J.; Bailey, Adam L.; Case, James Brett; Fremont, Daved H.; Klein, Robyn; Diamond, Michael S.; Boon, Adrianus C. M.
title: A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters
date: 2020-12-03
journal: bioRxiv
DOI: 10.1101/2020.12.02.408823
sha: 1d448648ba569d5899a85b0fa80d9884da18afd3
doc_id: 963514
cord_uid: kbxymn7y

The development of an effective vaccine against SARS-CoV-2, the etiologic agent of COVID-19, is a global priority. Here, we compared the protective capacity of intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in Golden Syrian hamsters. While immunization with ChAd-SARS-CoV-2-S induced robust spike protein specific antibodies capable or neutralizing the virus, antibody levels in serum were higher in hamsters immunized by an intranasal compared to intramuscular route. Accordingly, ChAd-SARS-CoV-2-S immunized hamsters were protected against a challenge with a high dose of SARS-CoV-2. After challenge, ChAd-SARS-CoV-2-S-immunized hamsters had less weight loss and showed reductions in viral RNA and infectious virus titer in both nasal swabs and lungs, and reduced pathology and inflammatory gene expression in the lungs, compared to ChAd-Control immunized hamsters. Intranasal immunization with ChAd-SARS-CoV-2-S provided superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract. These findings support intranasal administration of the ChAd-SARS-CoV-2-S candidate vaccine to prevent SARS-CoV-2 infection, disease, and possibly transmission.

The development of an effective vaccine against SARS-CoV-2, the etiologic agent of COVID-24 19, is a global priority. Here, we compared the protective capacity of intranasal and intramuscular 25 delivery of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike 26 protein (ChAd-SARS-CoV-2-S) in Golden Syrian hamsters. While immunization with ChAd-27 SARS-CoV-2-S induced robust spike protein specific antibodies capable or neutralizing the virus, 28 antibody levels in serum were higher in hamsters immunized by an intranasal compared to 29 intramuscular route. Accordingly, ChAd-SARS-CoV-2-S immunized hamsters were protected were scanned using the Hamamatsu NanoZoomer slide scanning system and head sections were 177 imaged using the Zeiss AxioImager Z2 system. Lung sections were scored according to a 178 previous publication [10] (<10% affected lung tissue = 1, >10% but <50% affected area = 2, >50% 179 affected area = 3). 180

Host response gene analysis. RNA extracted from hamster lung tissue homogenates was 181 used to synthesize cDNA using random hexamers and Superscript III (Thermo Scientific) with the 182 addition of RNase inhibitor according to the manufacturer's protocol. The expression of 22 183 inflammatory host genes was determined using PrimeTime Gene Expression Master Mix 184 (Integrated DNA Technologies) with primers/probe sets specific for C3, C5, Ccl2, Ccl3, Ccl5, Csf3, 185 Cxcl10, Ddx58, Ifit3, Ifng, Irf7, IL1b, IL4, IL5, IL6, IL7, IL10, IL12p40, IL15, Stat1, Stat6, and Tnfa 186 and results were normalized to Rpl18 and B2m levels. The primers and probes were derived from 187 previous publications [25] or developed in-house (see Table S1 ). Fold change was determined 188 using the 2-∆∆Ct method comparing immunized and SARS-CoV-2 challenged hamsters to naïve 189 controls. Development of the SARS-CoV-2 hamster model. To establish the utility of the hamster 195 model in our hands, we inoculated twenty-one 5-6 week old male hamsters IN with 2 x 10 5 plaque 196 forming units (PFU) of a fully infectious SARS-CoV-2 isolate in 100 µL of PBS. A control group of 197 three 5-6 week old male hamsters was inoculated with PBS. Mock-infected animals continued to 198 gain weight at a rate of ~2.4 grams or ~3% per day ( Fig 1A) . In contrast, SARS-CoV-2 inoculated 199 hamsters began to lose weight at 2 dpi, and this continued through days 4-5, at which point the 200 animals had lost approximately 10% of their body weight ( Fig 1A) . This decrease was associated 201 with a reduction in food intake between 1 and 4 dpi ( Fig 1B) . 202

At indicated time points after infection, hamsters were sacrificed, and tissues were collected 203 for analysis of viral burden, histology, and serological response. The left lung lobe was collected, 204 homogenized, and used to quantify SARS-CoV-2 N-gene copy number and infectious virus titer 205 by qPCR and focus-forming assay (FFA), respectively. Infectious virus titers peaked at 2 dpi with 206 8 x 10 5 focus forming units/mL (FFU/mL), and levels declined to low or undetectable by 5 dpi (Fig  207   1C ). SARS-CoV-2 N-gene copy number also peaked at 2 dpi at 10 10 copies per µL and gradually 208 declined to 10 5 -10 6 copies by 8 to 14 dpi ( Fig 1D) . The remainder of the lung tissue was fixed in 209 formalin, embedded, and sectioned for viral RNA in situ hybridization (ISH) and hematoxylin and 210 eosin (H & E) staining. SARS-CoV-2 viral RNA was detected by RNA-ISH at 2-5 dpi ( Fig 1E and  211 Fig S1) and was no longer detectable by 8 dpi. Viral RNA was localized to both airway and 212 alveolar epithelial cells (Fig S1) . Infection was accompanied by immune cell infiltration in 213 peribronchiolar and adjacent alveolar locations from 2 through 8 dpi (Fig 1E-F) , a pattern that is 214 consistent with bronchopneumonia. The immune cell infiltration was associated with alveolar 215 edema, exudate, tissue damage and intraparenchymal hemorrhage (Fig 1E-F) . Each of these 216 features of histopathology were markedly decreased by 14 dpi (Fig 1F) . 217

Serum samples were assayed for the presence of antibodies specific for purified, recombinant 218 S protein by ELISA. Low or undetectable antibody responses were detected through 4 dpi (Fig  219  1G . By day 5, S-specific IgG(H+L) responses were detected in all five animals, and the serum 220 antibody titer further increased between 8 and 14 dpi. 221

CoV-2 in hamsters. We assessed the immunogenicity of a replication-incompetent ChAd vector 223 encoding a prefusion-stabilized, full-length sequence of SARS-CoV-2 S protein (ChAd-SARS-224

CoV-2-S) [23] in Golden Syrian hamsters. We used a ChAd vector without a transgene (ChAd-225 control) as a control. Groups of ten 5-6 week-old male hamsters were immunized once via IN or 226 IM route with 10 10 virus particles of ChAd-control or ChAd-SARS-CoV-2-S. Serum was collected 227 prior to immunization or 21 days after, and antibody responses were evaluated by ELISA against 228 purified recombinant S and RBD proteins. Immunization with ChAd-SARS-CoV-2-S induced high 229 levels of anti-S and anti-RBD IgG(H+L) and IgG2/IgG3 antibodies 21 days later, whereas low or 230 undetectable levels of S-and RBD-specific antibodies were present in samples from ChAd-control 231 immunized animals (Fig 2A-F and Fig S2) . The antibody response was significantly higher after 232 IN than IM immunization (5 to 7-fold, P < 0.0001 for anti-S and anti-RBD respectively, Fig 2G-H) . 233

Serum samples also were tested for neutralization of infectious SARS-CoV-2 by focus-reduction 234 neutralization test (FRNT). As expected, pre-immunization sera or sera from hamsters immunized 235 with ChAd-control did not inhibit virus infection ( Fig 2I) . In contrast, sera from animals immunized 236 with ChAd-SARS-CoV-2-S neutralized infectious virus with geometric mean titers (GMT) of 237 1:1217 and 1:276 for IN and IM immunization routes, respectively ( Fig 2I) . 238

Immunization with Chimpanzee Ad-vectored vaccine protects hamsters from SARS-239

CoV-2 challenge. We next evaluated the protective effect of the ChAd vaccines in the hamster 240 SARS-CoV-2 challenge model. Golden Syrian hamsters immunized with ChAd-SARS-CoV-2-S 241 or ChAd-control were challenged IN with 2.5 x 10 5 PFU of SARS-CoV-2, and 2 dpi a nasal swab 242 was collected for viral burden analysis by qPCR and plaque assay. The N-gene copy number in 243 the ChAd-control immunized animals was ~10 9 copies per mL in both the IM and IN control groups 244 ( Fig 3A) . Immunization with ChAd-SARS-CoV-2-S reduced the N-gene copy number by 100-fold 245 in the IN (10 7 /mL) and 10-fold in the IM (10 8 /mL) immunized animals (P < 0.0001 and P < 0.001 246 respectively, Fig 3A) . N-gene copy number was significantly lower in the IN than IM immunized 247 animals (P < 0.05, Fig 3A) . At 2 dpi, infectious virus was detected by plaque assay in 4 of 20 248

ChAd-SARS-CoV-2-S-immunized animals and 15 of 20 ChAd-control immunized animals (Fig  249   3B) . At 3 dpi, six hamsters per group were sacrificed, and lungs were collected for viral burden 250 analysis (left lobe) by qPCR or FFA, or for histology (other lung lobes). In the control groups, we 251 detected 10 9 -10 10 copies of N-gene per mg of lung homogenate, and the mean infectious titer 252

was 6 x 10 4 FFU/mL. No difference was observed between the two control groups. Immunization 253

with ChAd-SARS-CoV-2-S vaccine significantly reduced the N-gene copy number (P < 0.01, Fig  254   3C ) and infectious titer in both the IN and IM immunized group ( Fig 3D) . A comparison between 255 IN and IM immunization revealed significantly lower N-gene copies per mg (788-fold, P < 0.01, 256 Fig 3C) , but not in infectious virus titer (P = 0.5, Fig 3D) , in the lungs of IN immunized animals. 257

The remaining four animals per group were monitored for weight loss for 10 days. The ChAd-258 control immunized animals lost an average of 4% and 8% of their starting body weight ( Fig 3E) . 259

Immunization with ChAd-SARS-CoV-2-S attenuated weight loss after SARS-CoV-2 challenge in 260 both groups (P < 0.01, Fig 3E) , with a possibly greater effect following IN immunization. To assess 261 if the ChAd-SARS-CoV-2-S vaccine induced sterilizing immunity by either of the immunization 262 routes, we collected the serum 10 dpi to test for the presence of antibodies against recombinant 263 NP by ELISA. A robust anti-NP IgG(H+L) ( Fig S3) and IgG2/3 ( Fig 3F) antibody response was 264 detected in all ChAd-control and ChAd-SARS-CoV-2-S immunized animals. 265

Immunization with Chimpanzee Ad-vectored vaccine minimizes lung pathology in 266 hamsters. To support these findings, we performed RNA in situ hybridization (RNA-ISH) and H 267 & E staining on sections from formalin-fixed lung tissues from immunized hamsters. RNA-ISH 268 detected viral RNA in all animals immunized with ChAd-control vaccine (Fig 4A-B and Fig S4) . 269

On average, ~20% of the section was positive for SARS-CoV-2 RNA. The presence of viral RNA 270 was associated with inflammation, tissue damage, and bronchopneumonia, as evidenced by 271 immune cell infiltration around bronchioles, alveolar edema, fluid exudates, and intraparenchymal 272 hemorrhage ( Fig S4) . In contrast, sections from animals immunized IM with ChAd-SARS-CoV-2-273 S contained no or few SARS-CoV-2 positive cells by RNA-ISH and inflammation was greatly 274 reduced (P < 0.01, Fig 4A-B and Fig S5) . No SARS-CoV-2 positive cells were detected following 275 IN immunization with ChAd-SARS-CoV-2-S (P < 0.01, Fig 4A-B and Fig S5) . challenge with SARS-CoV-2. RNA was extracted from the tissue homogenates and analyzed by 295 qRT-PCR using 24 different primer-probe sets specific for two housekeeping genes (ß2m and 296 Rpl18) and 22 different innate and inflammatory host genes (Table S1 ). Compared to five naïve 297 animals, expression of 8/22 inflammatory host genes (Ccl2, Ccl3, Cxcl10, Ddx58, Ifit3, IL10, 298

IL12p40, and Irf7 increased > 2-fold in the ChAd-Control immunized and SARS-CoV-2 challenged 299 animals ( Fig 5A) . A significant increase in gene-expression was observed for Ccl3, Ifit3, Cxcl10, 300

and Irf7 in both ChAd-Control-IN and ChAd-Control-IM animals (P < 0.05, Fig 5A) . ChAd-SARS-301

CoV-2-S immunization significantly reduced inflammatory gene expression after SARS-CoV-2 302 challenge ( Fig 5B) with the expression of a subset of host genes, such as Ccl5, Ccl3 and Cxcl10, 303 near normal levels. A comparison in host gene expression between IM and IN immunization 304 identified Irf7 and Ifit3 as two host genes whose expression was significantly (P < 0.01) lower in 305 the IN compared to IM immunized animals ( Fig 5B) . These data suggest that IN delivery of the 306

ChAd-vectored SARS-CoV-2-S vaccine provides greater protection against SARS-CoV-2 307 infection, inflammation, and disease in hamsters. 308

Effective vaccines against SARS-CoV-2 are needed to combat the devastating pandemic. In where the vaccinated hamsters lose between 0 and 5% of their body weight after challenge. 329

The reason for the higher antibody responses after IN versus IM immunization currently is not 330 known. One possibility is that the respiratory tract of the hamster is more permissive for the ChAd 331 virus than muscle, which could increase the amount of SARS-CoV-2-S antigen produced. Correlates of immune protection and SARS-CoV-2 associated disease were investigated in 373 our cohort of hamsters. Virus neutralization in serum correlated better with RBD-specific antibody 374 levels (r = 0.83, P < 0.0001) than S-protein specific responses (r = 0.31, P > 0.05, Fig S6) . Of the 375 three humoral response parameters, the virus neutralization serum titer (FRNT, IC50) correlated 376 best with weight loss 3 dpi (r = 0.59, P < 0.0001, Fig S6) . Weight loss at 3 dpi was strongly 377 associated with viral RNA levels (r = -0.68, P < 0.001) and infectious virus load (r = -0.62, P < 378 0.01, Fig S6) in the lungs, but not in the nasal swabs. Finally, inflammatory host gene-expression 379 hamsters sacrificed at different time points after inoculation (n = 5 for 2 dpi, n = 3 for 3 dpi, n = 3 567 for 4 dpi, n = 5 for 5 dpi, n = 2 for 8 dpi, n = 3 for 14 dpi, n = 3 for uninfected). after inoculation (n = 5 for 2 dpi, n = 3 for 3 dpi, n = 3 for 4 dpi, n = 5 for 5 dpi, n = 2 for 8 dpi, n = 624 3 for 14 dpi, n = 3 for uninfected). Figure S4 A B 

STAT2 signaling 439 restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

A single-dose live-442 attenuated YF17D-vectored SARS-CoV2 vaccine candidate

Favipiravir 444 at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine 445 lacks activity

Hydroxychloroquine 448 prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. JCI insight

Favipiravir antiviral efficacy 451 against SARS-CoV-2 in a hamster model

Antiviral 453 treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of 454 effect for hydroxychloroquine

Ad26 vaccine 456 protects against SARS-CoV-2 severe clinical disease in hamsters

A Newcastle disease virus (NDV) 459 expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine

A single dose of 463 recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge

ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2

A highly conserved cryptic epitope in the 469 receptor binding domains of SARS-CoV-2 and SARS-CoV

Validation of assays to monitor immune 473 responses in the Syrian golden hamster (Mesocricetus auratus)

Elevated ACE-2 477 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 478 entry and replication

Current prospects and future challenges for nasal vaccine delivery

PubMed 482 PMID: 27936348

Recent progress in mucosal vaccine development: potential and limitations

Supplementary Table 1: Primers and probe sets used to quantify gene expression in the 663